ERBB2 and breast carcinoma: NCT04334330 (62)A Phase II study to Evaluate the Efficacy of Palbociclib, Trastuzumab and Pyrotinib With Fulvestrant in ER/PR+ and HER2+ breast cancer patients with brain metastasis